NCT06239870View on ClinicalTrials.gov

Single-arm, Single-center, Exploratory Phase II Clinical Study of Envafolimab Combined With Chemoradiotherapy in the Treatment of Locally Advanced pMMR/MSS Rectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

April 1, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Envafolimab Combined With Chemoradiotherapy in the Treatment of Locally Advanced pMMR/MSS Rectal Cancer
Interventions
DRUG

Envafolimab combined with chemoradiotherapy in the whole course of neoadjuvant therapy

Each enrolled patient was given 2 cycles of induction chemotherapy combined with immunization, followed by immunization combined with chemoradiotherapy, and finally 2 cycles of consolidation chemotherapy combined immunization

Trial Locations (1)

650000

RECRUITING

Envafolimab, Kunming

All Listed Sponsors
collaborator

Beijing Bethune Charitable Foundation

UNKNOWN

lead

Yunnan Cancer Hospital

OTHER